George:
SGEN.... some of the projects appear to be inherited, to me. The focus definitely is, IMO.
The company is sort of trickle down.... Genetic Systems ------> Oncogen -------> Bristol-Myers Squibb Research Institute ------> SGEN.
The concepts are old. Some of the targets are old. They were, IMO, just something to take off with, something that Siegall and Fell felt they could run with. To me, when the company was new and shiny it looked 20 years old and tired. And I didn't like Dr. Fell, at all (many apparently didn't.... he was kicked up to Chair and then, subsequently, out completely). And there's at least one phenomenologist on the Board who, IMO, has done more harm to the field of cancer immunology than good.
I like the ADC partners. The partners, for that matter, look great overall.
Thanks, I'll take a closer look. I don't like immunotoxins (a bit close to home), but I didn't know about the strong focus on ADC.
Nice post. That's the sort of effort that makes op for all of us. Thanks.
Rick |
